Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

Detalles Bibliográficos
Autores principales: Sáez-Llorens, Xavier, Lanata, Claudio, Aranguren, Elaine, Celis, Carlos R., Cornejo, Rubelio, DeAntonio, Rodrigo, Ecker, Lucie, Garrido, Diegi, Gil, Ana I., Gonzales, Marina, Hess-Holtz, Morgan, Leroux-Roels, Geert, Junker, Helga, Kays, Sarah-Katharina, Koch, Sven D., Lazzaro, Sandra, Mann, Philipp, Quintini, Gianluca, Srivastava, Barkha, Vahrenhorst, Dominik, von Eisenhart-Rothe, Philipp, Wolz, Olaf-Oliver, Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139920/
https://www.ncbi.nlm.nih.gov/pubmed/37131960
http://dx.doi.org/10.1016/j.jvacx.2023.100307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139920/
https://www.ncbi.nlm.nih.gov/pubmed/37131960
http://dx.doi.org/10.1016/j.jvacx.2023.100307

Ejemplares similares